Objective: To assess effectiveness and tolerability of first-line and conversion to lacosamide monotherapy for focal seizures.
| INTRODUC TI ON
The aim of epilepsy treatment is to achieve seizure freedom without clinically significant adverse effects. 1 The majority of patients with epilepsy attain seizure freedom with a single antiepileptic drug (AED), either as initial monotherapy or as a subsequent monotherapy substitution. 2 Theoretically, monotherapy for the treatment of epilepsy has a number of advantages over polytherapy including a reduced likelihood of adverse events (AEs) and drug-drug interactions, improved compliance and reduced likelihood of pregnancy complications. 3, 4 Lacosamide is approved for the treatment of focal (partialonset) seizures with or without secondary generalization as monotherapy and adjunctive therapy (≥16 years of age) in the European Union (EU) 5 and in the United States (US) (≥17 years of age). 6 Its efficacy as monotherapy in patients with focal seizures has been demonstrated in two double-blind randomized trials; a headto-head non-inferiority trial of lacosamide vs the continuousrelease (CR) formulation of carbamazepine used for EU approval (SP993) 7 ; and a historical-controlled, conversion to monotherapy trial (SP902) for US approval. 8 In the SP993 non-inferiority trial in patients with newly diagnosed epilepsy, 73.6% of lacosamidetreated and 69.7% of carbamazepine-CR-treated patients (Full Analysis Set) completed 6 months on last evaluated dose without a seizure.
Randomized controlled trials are considered the gold standard in assessing efficacy, but many of these trials can be restrictive in design with fixed titration schedules, and doses that are not reflective of clinical practice. 9 As per trial design, patients with certain clinical characteristics and comorbidities may be excluded, further limiting the applicability of the trial results to a wider population of patients. Observational studies may complement findings from randomized controlled trials by assessing the effectiveness of an intervention in the patients encountered in daily clinical practice.
In observational studies, physicians are free to individualize titration and maintenance dosages to optimize efficacy and tolerability. 9 Additionally, observational studies often have a longer duration and more diverse patient populations, including patients with comorbidities commonly excluded from randomized controlled trials, which means that they may be more likely to detect rare or lateonset adverse events (AEs) compared with short-term, randomized controlled trials. 9 Although the long-term use of lacosamide monotherapy has been
assessed in an open-label extension to SP902 after conversion to monotherapy-where, of the 151 patients who received lacosamide monotherapy for the duration of their participation in the study, 107
had a longest monotherapy duration of ≥24 months-there is limited published clinical practice experience with lacosamide monotherapy.
A number of smaller open-label and retrospective studies in Europe have included patients receiving lacosamide as monotherapy, [10] [11] [12] [13] [14] usually after conversion to monotherapy. In a prospective study, 58 patients converted to lacosamide monotherapy and the majority (63.8%) remained on lacosamide monotherapy after 1 year; 55%
were seizure free for the treatment period. 
| ME THODS

| Design
This chart review had a retrospective observation period of 12 months (±3 months) with a historical baseline of 6 months prior to Day 1 (day of first administration of lacosamide monotherapy).
Observation points (OP) were the first day of lacosamide monotherapy (OP1), and 6 (±3) and 12 (±3) months after initiating treatment (OP2 and OP3). The last documented OP had to take place prior to initiation of the chart review; therefore, data collection did not have any influence on treatment decisions. The choice of treatment was made independently by the physician, according to standard clinical practice.
| Patients
Participating sites reviewed patient charts to identify individuals aged ≥16 years with focal seizures (with or without evolution to bilateral tonic-clonic seizures; using the latest ILAE seizure classifica- 
| Outcome measures
The primary outcome was retention on lacosamide monotherapy after at least 12 months of treatment. Secondary outcomes included the proportion of patients who were seizure free at ~6 months (OP2) and at ~12 months (OP3), number of emergency room (ER) visits and number and duration of hospitalizations.
Safety and tolerability variables were the reported frequency of adverse drug reactions (ADRs), discontinuation of lacosamide due to ADRs, and serious ADRs. An ADR was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that was temporally associated with the use of that pharmaceutical product and that was assessed by the reporter and/or the sponsor as "related" to the administration of the pharmaceutical product. A serious ADR was defined as an ADR that met one or more of the following criteria:
death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect (including that occurring in a foetus), important medical event, initial inpatient hospitalization or prolongation of hospitalization.
| Analysis
All analyses were exploratory in nature and missing values were not imputed. Safety variables were analysed using the Safety Set (all patients in the database who had been treated with at least one dose of lacosamide). Effectiveness and efficacy variables were analysed using the Full Analysis Set (FAS; all patients in the Safety Set
[SS] who had post-baseline data). Additional predefined subanalyses were performed for patients who received lacosamide as first-line monotherapy vs those converting from another AED monotherapy, for those who were aged <65 years vs those aged ≥65 years, and for those patients converting to lacosamide monotherapy who had received ≤3 vs >3 lifetime AEDs before initiating lacosamide monotherapy. All seizure freedom rates were calculated on the FAS population implying that all-cause discontinuations are considered as not seizure free.
| Sample size
Assuming a conservative retention rate of 50% (based on the retention rates observed in a German retrospective study of adjunctive lacosamide (data on file) and an Italian prospective study of conversion to lacosamide monotherapy, 10 63% and 63.8%, respectively) and a sample size of 400 patients, two-sided 95% confidence interval (CI) covered the estimated retention rate with a precision of <5%.
| RE SULTS
A total of 439 patients were included in the chart review and were evaluable for both effectiveness (FAS) and safety (SS) analyses; 98 (22.3%) patients had initiated lacosamide as first-line monotherapy; 341 (77.7%) had converted to lacosamide monotherapy from their previous AED treatment ( Figure 1 
| Retention rate
The retention rates in first-line monotherapy and conversion to monotherapy patients after at least 12 months' treatment were 60.2% 
| Seizure freedom
At OP2, 66.3% of first-line monotherapy patients and 63.0% of conversion to monotherapy patients were seizure free. At OP3, seizure freedom rates were 60.2% and 52.5% for first-line and conversion to monotherapy patients, respectively ( Figure 3 ). In conversion to monotherapy patients, the seizure freedom rates at OP2 in patients who had previously received ≤3 
| Emergency room visits and hospitalizations
A total of seven patients (1.6%) visited an ER during the historical baseline period, all due to epilepsy. During the observation period, 11 patients (2.5%) had a documented ER visit while receiving lacosamide monotherapy. Of these, nine patients had one ER visit, one had two visits, and one had nine visits. Epilepsy was the documented reason for ER visits for four patients (0.9%). Duration of hospitalization was usually short both during the historical baseline period and during the study duration (median: 1 day). In patients aged ≥65 years, four patients visited the ER, all for reasons other than epilepsy.
Three patients had one visit and one had two visits. Six patients aged <65 years had one ER visit and one patient had more than four ER visits. Four patients visited the ER due to epilepsy and four for reasons other than epilepsy, ADRs or elective procedures.
| Safety and tolerability
ADRs were documented for 52 patients (11.8%) ( 
| D ISCUSS I ON
This was a retrospective chart review of patients with focal seizures who received lacosamide either as first-line monotherapy or after converting to lacosamide monotherapy in specialist epilepsy centres.
Retention rates after approximately 12 months of treatment (OP3) were comparable in patients who had converted to lacosamide monotherapy vs those who received first-line lacosamide monotherapy. However, using Kaplan-Meier methodology to censor for missing data, the estimated retention rate among patients converting to lacosamide monotherapy was higher than that for first-line monotherapy patients. Retention rates were higher in conversion to monotherapy patients aged ≥65 years compared with younger patients.
There was no difference in retention rates between age groups in first-line monotherapy patients. Retention rates in the current trial were comparable with those observed in a single-centre, open-label study in 58 patients who converted to monotherapy after they had experienced 1-year seizure freedom with adjunctive lacosamide. 10 Moreover, these retention rates are also consistent with the 59.3% retention rate at 1 year described in a study of 59 adults receiving lacosamide in adjunctive use. 18 When comparing to Kaplan-Meier estimates the 1-year retention rates in our study are higher than those described in another long-term follow-up study with lacosamide in adjunctive use (74.5% Kaplan-Meier estimates). 19 However, this may be due to the less severe patient population included into our study.
In general, seizure freedom rates were lower at ~12 months (OP3) than at ~6 months (OP2) but were higher in patients who received lacosamide as first-line monotherapy compared with those who converted to monotherapy (60.2% and 52.5%, respectively, at Lacosamide was generally well tolerated with a low frequency of ADRs (11.8% in the overall population). The recorded ADRs were consistent with those observed in clinical trials of lacosamide as monotherapy and as adjunctive therapy, 7, 8, 20 and the incidence of ADRs was comparable between first-line monotherapy and conversion to monotherapy patients. Dizziness was the most commonly documented ADR in the overall and elderly population (5.0% and 8.6%, respectively); however, the incidence of dizziness was lower than that observed in a Phase III trial in newly diagnosed epilepsy (12%) 7 and considerably lower than in a conversion to monotherapy trial (24.0%) using a fixed titration schedule for lacosamide before the withdrawal of the baseline drugs. were lower than those used as adjunctive therapy in a similar retrospective study in Spain 22 and a prospective observational study in Germany. 23 Lacosamide doses used by conversion to monotherapy patients (median 300 mg [min, max: 50, 600]) were comparable to those used in these two studies.
Interpretation of the results of this study is limited by the retrospective design of the study, potential inclusion bias, and the ex- 
| CON CLUS IONS
The results of this retrospective, non-interventional chart review indicate that lacosamide monotherapy may be an effective treatment option for focal seizures in patients receiving their first AED monotherapy and for those converting to lacosamide monotherapy from other AEDs.
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